News

Analyses presented at ASH 2021 find statistical models can predict risk of early death with non-intensive AML therapy

Results at SABCS show assay has prognostic value that complements value of recurrence score in postmenopausal patients

RxPONDER finds postmenopausal women with HR+, HER2- breast cancer with 1-3 involved nodes and an RS of 25 or less can safely skip chemo

Forty years of publicly funded trials added 14 million years of life for cancer patients and profoundly affected cancer care guidelines

A blood serum test can identify which patients have slow-growing disease that might be controlled with an aromatase inhibitor alone.

Study of federally funded research finds overall enrollment to treatment trials changed little, while enrollment to cancer control and prevention studies fell substantially.

Pretreatment fatigue can mean worse survival outcomes for patients with cancer